Gastric Cancer | Tumor

CURE’s gastric cancer page is a go-to resource for oncology news and updates in the world of gastric cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in gastric cancer.

Drug Combo May Prevent Chemo-Induced Nausea and Vomiting in Some Patients

August 31st 2021, 3:00pm

Article

Aprepitant, palonosetron and dexamethasone curbed chemotherapy-induced nausea and vomiting in certain women with gastrointestinal cancers who were receiving FOLFIRI or FOLFOX regimens.

FDA Approves Jemperli for Certain Advanced Solid Tumors

August 17th 2021, 10:29pm

Article

The indication for the PD-1 blocking antibody now includes adults with mismatch repair-deficient recurrent or advanced disease, adding to the previous indication of endometrial solid tumors.

Staying Aware of Gastric Cancer Risk Factors in Young Adults

August 13th 2021, 1:00pm

Article

On behalf of Hope for Stomach Cancer, Dr. Yanghee Woo speaks with CURE® about risk factors for gastric cancer and the alarming rise in cases in young adults.

Looking Forward: Patients With Genetic Mutations Are Empowered to Make Plans

August 6th 2021, 9:00pm

Article

Knowing they’ve inherited a genetic mutation for stomach or breast cancer gives patients the power to plan ahead.

FDA’s Approval of Keytruda-Based Regimen for Certain Stomach Cancer Subtypes ‘Really Exciting’ For Patients

July 23rd 2021, 11:00pm

Article

The FDA’s recent approval of Keytruda in combination with trastuzumab and chemotherapy in the first-line setting is an exciting change for a group of patients with certain subtypes of stomach cancer, according to an expert.

Treating Cancer as Patients Age

July 20th 2021, 3:00pm

Article

As patients aged 65 or older receive a diagnosis of cancer, their treatment course and priorities may differ from their younger counterparts.

New Potential Immunotherapy Treatment Options in Advanced Esophageal Squamous Cell Carcinoma

June 28th 2021, 3:00pm

Video

Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma.

Opdivo Combined with Yervoy or Chemo Improves Survival in Unresectable and Advanced Esophageal Cancer

June 5th 2021, 3:00pm

Article

Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.

FDA Approves Opdivo for Adjuvant Treatment of Esophageal and Gastroesophageal Junction Cancer

May 20th 2021, 6:17pm

Article

Opdivo was approved by the FDA for use if disease persisted after neoadjuvant chemoradiotherapy in these patients, which is “exciting news,” as patients would typically undergo surveillance when this occurred.

FDA Approves Keytruda for Use With Trastuzumab and Chemotherapy for Subtypes of Stomach Cancer

May 5th 2021, 6:58pm

Article

Based on findings from the KEYNOTE-811 trial, the FDA approved Keytruda for the treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and chemotherapy.